Uncategorized
Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals announces that the NDA for KPI-121 0.25% has been accepted for review by the U.S. FDA.